Verocytotoxin E. coli Review: Karmali (1989)
The Definitive Early Synthesis: Karmali (1989)
The study: Karmali MA. (1989). Infection by verocytotoxin-producing Escherichia coli. Clinical Microbiology Reviews, 2(1), 15–38.
Six years after his one-page Lancet report linked cytotoxin-producing E. coli to hemolytic-uremic syndrome, Mohamed Karmali wrote the review that organized the entire field: “Infection by verocytotoxin-producing Escherichia coli,” 24 pages in Clinical Microbiology Reviews. It synthesized the clinical spectrum, the epidemiology, the microbiology, and the toxin biology — the complete picture of the VTEC/STEC problem as understood at the end of the 1980s, written by the investigator who started it.
The clinical spectrum, organized
The review’s clinical synthesis — hemorrhagic colitis, HUS, thrombotic thrombocytopenic purpura, the asymptomatic infections — arranged the disease manifestations into the spectrum the field still uses. The HUS pathogenesis (the toxin-mediated endothelial damage, the renal microangiopathy, the age distribution concentrating in children) was explained with the evidence then available. The review didn’t just list diseases; it connected the toxin’s biology to the clinical outcomes — the mechanistic thinking that guides the clinical management.
The epidemiology of the 1980s
The review captured the outbreak epidemiology of the discovery decade: the hamburger-associated O157:H7 outbreaks (the Riley investigations, the emerging pattern), the sporadic cases, the cattle reservoir evidence accumulating, the food vehicles beyond beef beginning to appear. Reading it now, the epidemiology section is the time capsule — the field at the moment the problem’s scale was becoming clear but before the produce outbreaks, the genomic era, and the global surveillance reshaped the picture.
The toxin biology
The verocytotoxin/Shiga toxin biology — the AB5 structure, the receptor binding (Gb3), the ribosomal inactivation, the phage-encoded toxin genes — was synthesized comprehensively. The review explained why the toxin causes what it causes: the receptor distribution determining the target organs, the toxin’s potency explaining the low infectious dose’s severe consequences. The molecular biology was early (the cloning work just published) but the framework was right — and it guided the subsequent decades of toxin research.
The diagnostic and control implications
The review’s practical sections — the laboratory diagnosis (the sorbitol-MacConkey screening, the toxin detection, the serotyping), the treatment cautions (the early warnings about antibiotics and antimotility agents that the subsequent evidence confirmed), the prevention (the cattle reservoir, the food hygiene, the pasteurization) — translated the science into the clinical and public health practice. The antibiotic caution, stated carefully in 1989, became one of the field’s firmest recommendations.
Why the review matters historically
The 1989 review is the bridge between the discovery (1983) and the mature field (1990s onward): the document that took the scattered findings and made them a discipline. Karmali’s unique position — the discoverer turned synthesizer — gave it authority; its comprehensiveness gave it durability. The specific details are dated (the epidemiology, the methods), but the structure — clinical, epidemiological, microbiological, practical — is the template every subsequent STEC review follows. The field’s memory of its own origins lives in this paper.
The review’s clinical-laboratory bridge
The Karmali 1989 review’s clinical-laboratory bridge — the HUS and the hemorrhagic colitis (the bedside) connected to the verotoxin detection and the serotyping (the bench) — is the translational structure the field needed: the clinicians understanding the laboratory, the laboratorians understanding the disease. The review’s dual audience (the clinical microbiologists, the infectious-disease physicians) reflects the verocytotoxin E. coli‘s dual nature. The bridge the review built still carries the traffic.
Source: Karmali MA. (1989). Infection by verocytotoxin-producing Escherichia coli. Clinical Microbiology Reviews, 2(1), 15–38.